Anu E. Meerwaldt

Anu E. Meerwaldt

Auto-generated profile, based on publicly available information

Anu E. Meerwaldt

Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in JACC: Cardiovascular Imaging
Verified
Journal Article
Open access
MSMax L. Senders
Max L. Senders
Sophie HernotSophie Hernot
Sophie Hernot
GCGiuseppe Carlucci
Giuseppe Carlucci
JVJan C. van de Voort
Jan C. van de Voort
FFFrancois Fay
Francois Fay
CPCarlos Pérez-Medina
Carlos Pérez-Medina
This study sought to develop an integrative positron emission tomography (PET) with magnetic resonance imaging (MRI) procedure for accurate atherosclerotic plaque phenotyping, facilitated by clinically approved and nanobody radiotracers. Noninvasive characterization of atherosclerosis remains a challenge in clinical practice. The limitations of current diagnostic methods demonstrate that, in addition to atherosclerotic plaque morphology and composition, disease activity needs to be evaluated. We screened 3 nanobody radiotracers targeted to different biomarkers of atherosclerosis progression, namely vascular cell adhesion molecule (VCAM)-1, lectin-like oxidized low-density lipoprotein receptor (LOX)-1, and macrophage mannose receptor (MMR). The nanobodies, initially radiolabeled with copper-64 (64Cu), were extensively evaluated in Apoe-/- mice and atherosclerotic rabbits using a combination of in vivo PET/MRI readouts and ex vivo radioactivity counting, autoradiography, and histological analyses. The 3 nanobody radiotracers accumulated in atherosclerotic plaques and displayed short circulation times due to fast renal clearance. The MMR nanobody was selected for labeling with gallium-68 (68Ga), a short-lived radioisotope with high clinical relevance, and used in an ensuing atherosclerosis progression PET/MRI study. Macrophage burden was longitudinally studied by 68Ga-MMR-PET, plaque burden by T2-weighted MRI, and neovascularization by dynamic contrast-enhanced (DCE) MRI. Additionally, inflammation and microcalcifications were evaluated by fluorine-18 (18F)-labeled fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (18F-NaF) PET, respectively. We observed an increase in all the aforementioned measures as disease progressed, and the imaging signatures correlated with histopathological features. We have evaluated nanobody-based radiotracers in rabbits and developed an integrative PET/MRI protocol that allows noninvasive assessment of different processes relevant to atherosclerosis progression. This approach allows the multiparametric study of atherosclerosis and can aid in early stage anti-atherosclerosis drug trials.

20 April 2020 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
MSMax L. Senders
Max L. Senders
AMAnu E. Meerwaldt
Anu E. Meerwaldt
MLMandy M. T. van Leent
Mandy M. T. van Leent
BSBrenda L. Sanchez-Gaytan
Brenda L. Sanchez-Gaytan
JVJan C. van de Voort
Jan C. van de Voort
WMWillem J. M. Mulder
Willem J. M. Mulder

1 January 2018 in JACC
Verified
Journal Article
Closed access
MSMax L. Senders
Max L. Senders
XQXuchu Que
Xuchu Que
YCYoung Seok Cho
Young Seok Cho
CYCalvin Yeang
Calvin Yeang
HGHannah Groenen
Hannah Groenen
STSotirios Tsimikas
Sotirios Tsimikas

5 March 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
MLMandy M. T. van Leent
Mandy M. T. van Leent
AMAnu E. Meerwaldt
Anu E. Meerwaldt
ABAlexandre Berchouchi
Alexandre Berchouchi
YTYohana C. Toner
Yohana C. Toner
MBMarianne E. Burnett
Marianne E. Burnett
ATAbraham J. P. Teunissen
Abraham J. P. Teunissen
Modular production methods allow the efficient development of nanoimmunotherapies targeting the innate immune system.

1 October 2020 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
MNMatthias Nahrendorf
Matthias Nahrendorf
FHFriedrich Felix Hoyer
Friedrich Felix Hoyer
AMAnu E. Meerwaldt
Anu E. Meerwaldt
MLMandy M.T. van Leent
Mandy M.T. van Leent
MSMax L. Senders
Max L. Senders
WMWillem J.M. Mulder
Willem J.M. Mulder
Background: Macrophages, innate immune cells that reside in all organs, defend the host against infection and injury. In the heart and vasculature, inflammatory macrophages also enhance tissue damage and propel cardiovascular diseases. Methods: We here use in vivo positron emission tomography (PET) imaging, flow cytometry, and confocal microscopy to evaluate quantitative noninvasive assessment of cardiac, arterial, and pulmonary macrophages using the nanotracer 64 Cu-Macrin—a 20-nm spherical dextran nanoparticle assembled from nontoxic polyglucose. Results: PET imaging using 64 Cu-Macrin faithfully reported accumulation of macrophages in the heart and lung of mice with myocardial infarction, sepsis, or pneumonia. Flow cytometry and confocal microscopy detected the near-infrared fluorescent version of the nanoparticle ( VT680 Macrin) primarily in tissue macrophages. In 5-day-old mice, 64 Cu-Macrin PET imaging quantified physiologically more numerous cardiac macrophages. Upon intravenous administration of 64 Cu-Macrin in rabbits and pigs, we detected heightened macrophage numbers in the infarcted myocardium, inflamed lung regions, and atherosclerotic plaques using a clinical PET/magnetic resonance imaging scanner. Toxicity studies in rats and human dosimetry estimates suggest that 64 Cu-Macrin is safe for use in humans. Conclusions: Taken together, these results indicate 64 Cu-Macrin could serve as a facile PET nanotracer to survey spatiotemporal macrophage dynamics during various physiological and pathological conditions. 64 Cu-Macrin PET imaging could stage inflammatory cardiovascular disease activity, assist disease management, and serve as an imaging biomarker for emerging macrophage-targeted therapeutics.

6 January 2023 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
AMAnu E Meerwaldt
Anu E Meerwaldt
MSMilou Straathof
Milou Straathof
WOWija Oosterveld
Wija Oosterveld
CHCaroline L van Heijningen
Caroline L van Heijningen
MLMandy Mt van Leent
Mandy Mt van Leent
RDRick M Dijkhuizen
Rick M Dijkhuizen
Recanalization therapy after acute ischemic stroke enables restoration of cerebral perfusion. However, a significant subset of patients has poor outcome, which may be caused by disruption of cerebral energy metabolism. To assess changes in glucose metabolism subacutely and chronically after recanalization, we applied two complementary imaging techniques, fluorodeoxyglucose (FDG) positron emission tomography (PET) and deuterium (2H) metabolic imaging (DMI), after 60-minute transient middle cerebral artery occlusion (tMCAO) in C57BL/6 mice. Glucose uptake, measured with FDG PET, was reduced at 48 hours after tMCAO and returned to baseline value after 11 days. DMI revealed effective glucose supply as well as elevated lactate production and reduced glutamate/glutamine synthesis in the lesion area at 48 hours post-tMCAO, of which the extent was dependent on stroke severity. A further decrease in oxidative metabolism was evident after 11 days. Immunohistochemistry revealed significant glial activation in and around the lesion, which may play a role in the observed metabolic profiles. Our findings indicate that imaging (altered) active glucose metabolism in and around reperfused stroke lesions can provide substantial information on (secondary) pathophysiological changes in post-ischemic brain tissue.